Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq:CHRS), today announced that effective February 1, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 22,500 shares of the common stock of the Company to three newly hired employees with a per share exercise price of $8.65, the closing trading price on the grant date.
Related news for (CHRS)
- Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
- Coherus Divesting UDENYCA Franchise to Intas Pharmaceuticals for up to $558M
- Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
- Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
- Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium